Milrinone

Base Information Edit

Chemical Name:Milrinone
CAS No.:78415-72-2
Molecular Formula:C12H9N3O
Molecular Weight:211.223
Hs Code.:29337900
European Community (EC) Number:278-903-6
NSC Number:760072
UNII:JU9YAX04C7
DSSTox Substance ID:DTXSID5023324
Nikkaji Number:J23.655A
Wikipedia:Milrinone
Wikidata:Q847399
NCI Thesaurus Code:C61848
RXCUI:52769
Pharos Ligand ID:HFTSHTBFLM9Q
Metabolomics Workbench ID:42637
ChEMBL ID:CHEMBL189
Mol file:78415-72-2.mol

Synonyms:Corotrop;Corotrope;Lactate, Milrinone;Milrinone;Milrinone Lactate;Primacor;Win 47203;Win-47203;Win47203

Suppliers and Price of Milrinone

Supply Marketing:Edit

Business phase:: The product has achieved commercial mass production^*data from LookChem market partment

Manufacturers and distributors:

Manufacture/Brand
Chemicals and raw materials
Packaging
price

Usbiological
Milrinone
5mg
$ 340.00

Usbiological
Milrinone
10mg
$ 446.00

TRC
Milrinone
10mg
$ 80.00

TRC
Milrinone
1g
$ 375.00

Tocris
Milrinone ≥98%(HPLC)
50
$ 802.00

Tocris
Milrinone ≥98%(HPLC)
10
$ 191.00

TCI Chemical
Milrinone >98.0%(N)
100mg
$ 79.00

TCI Chemical
Milrinone >98.0%(N)
1g
$ 316.00

Sigma-Aldrich
Milrinone ≥97% (TLC), powder
50mg
$ 825.00

Sigma-Aldrich
Milrinone United States Pharmacopeia (USP) Reference Standard
500mg
$ 612.00

Total 182 raw suppliers

Chemical Property of Milrinone Edit

Chemical Property:

Appearance/Colour:Crystalline solid
Melting Point:>3000C
Refractive Index:1.5700 (estimate)
Boiling Point:448.685 °C at 760 mmHg
PKA:7.21±0.10(Predicted)
Flash Point:225.157 °C
PSA：69.54000
Density:1.288 g/cm³
LogP:1.61698
Storage Temp.:2-8°C
Solubility.:DMSO: >10 mg/mL
Water Solubility.:Soluble in DMSO. Insoluble in water.
XLogP3:0
Hydrogen Bond Donor Count:1
Hydrogen Bond Acceptor Count:3
Rotatable Bond Count:1
Exact Mass:211.074561919
Heavy Atom Count:16
Complexity:419

Purity/Quality:

99% ^*data from raw suppliers

Milrinone ^*data from reagent suppliers

Safty Information:

Pictogram(s): T, T+
Hazard Codes:T,T+
Statements: 23/24/25-26/27/28
Safety Statements: 36/37/39-45-22

MSDS Files:: SDS file from LookChem

Useful:

Canonical SMILES:CC1=C(C=C(C(=O)N1)C#N)C2=CC=NC=C2
Recent ClinicalTrials:Cerebral Hemodynamic Optimization by Milrinone to Prevent Delayed Cerebral Ischemia
Recent EU Clinical Trials:The effect of milrinone on central and regional blood flow in preterm neonates undergoing patent ductus arteriosus ligation.
Drug Interactions Patients already receiving angiotensin-converting enzyme inhibitor therapy using milrinone can further improve hemodynamics, but also increase the side effects caused by the blood vessels dilation. Milrinone combinated with mid-dose dobutamine, can enhance the positive inotropic effect, further reducing left ventricular end-diastolic pressure. When there is low blood pressure, milrinone can theoretically combine a larger dose dopamine.
Uses New non-glycosides non-catecholamines cardiac drug , its function is similar to amrinone ,positive inotropic effect is strong and about 20 to 50 times of amrinone, and it has significant effect on expanding smooth muscle,it can reduce the load on the heart, it can also improve kidney and muscle blood supply. Oral and intravenous are valid, no serious adverse reactions. It is used For severe heart failure such as chronic heart failure and congestive heart failure. bronchodilator Selective phosphodiesterase inhibitor with vasodilating and positive inotropic activity. Cardiotonic It is used (particularly intravenously, as the lactate) for the short-term management of severe heart failure. Milrinone inhibits the action of phosphodiesterase-3 preventing degradation of cAMP. The corresponding increase in cAMP levels leads to increased activation of protein kinase A. It is a selective phosphodiesterase inhibitor with vasodilating and positive inotropic activity.
production method Method 1: 4-methylpyridine is dissolved in anhydrous diethyl ether, under protection of nitrogen, a solution of phenyl lithium in diethyl ether is added dropwise with stirring at room temperature, the reaction is continued. Nitrogen is stopped, cool to 0 ℃, ethyl acetate is added dropwise at below 10 ℃. With concentrated hydrochloric acid to Ph = 1~2, the aqueous layer is separated, basify with saturated sodium carbonate to Ph = 9, precipitate oil , extract several times with chloroform, dry, chloroform is distilled off, vacuum distillation, collecting 130-132 ℃/1.47kPa of fractions, namely, 1-(4-pyridyl) acetone. 1-(4-pyridyl) acetone, acetonitrile, and N, N-dimethylformamide dimethyl acetal are refluxed together. The solvent is distilled off under reduced pressure, the residue is dissolved in an appropriate amount of chloroform and an alumina column (Soxhlet)is heated at reflux for extraction, concentrate extract, with carbon tetrachloride-cyclohexane (4: 1) recrystallize to give 1-(4-pyridyl)-2-(dimethylamino) ethenyl methyl ketone. 1-(4-pyridyl)-2-(dimethylamino) ethenyl methyl ketone, cyano acetamide, sodium methoxide and dimethyl formamide are heated under reflux, the solvent is distilled off under reduced pressure, the residue is added acetonitrile, warm to dissolve , cool to 10 ℃; the precipitated solid is filtered, dissolve with amount of water, decolorize with charcoal, and acidify with hydrochloric acid 6mol/L to Ph = 6.5~7, the precipitated solid is recrystallized from dimethylformamide to give pale yellow granular crystals, which are milrinone, mp> 300 ℃. Method 2: use 4-pyridyl acetone as a raw material, after condensation with triethyl orthoformate, it reacts with 2-cyanoacetamide, to obtain milrinone. Method 3: pyridyl acetone reacts with 2,2-cyano-vinyl ethyl ether reaction to generate milrinone.
Description Milrinone, an inhibitor of phosphodiesterase selective for fraction III PDE, exerts a positive inotropic effect on the heart as well as a peripheral vasodilatory effect. Milrinone given intravenously produces significant improvements on cardiac output, pulmonary capillary wedge pressure and vascular resistance without significant effects on the heart rate. Milrinone is an inhibitor of type 3 phosphodiesterases (PDEs), inhibiting recombinant PDE3A and PDE3B with IC50 values of 0.45 and 1 μM, respectively. It is selective for PDE3 over PDE1, PDE2, PDE4, PDE5, and PDE7 (IC50s = 263, >300, 17.5, 49.1, and 58.3 μM, respectively). Milrinone (0.1-1 mg/kg) has positive inotropic effects, increasing cardiac contractile force in anesthetized dogs with a concomitant increase in heart rate but not blood pressure. It also increases contractile force in models of propranolol- and verapamil-induced heart failure in anesthetized dogs when administered at an initial dose of 30 μg/kg followed by a continuous 3 μg/kg per minute infusion. Milrinone has vasodilatory effects as well, decreasing mean aortic pressure and increasing venous compliance in anesthetized dogs when administered at an initial dose of 10 μg/kg followed by a continuous 1.7-2.4 μg/kg per minute infusion. Formulations containing milrinone have been used in the treatment of heart failure.

Technology Process of Milrinone

There total 34 articles about Milrinone which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield: 93.4%